|
FR2435905A1
(fr)
*
|
1978-09-13 |
1980-04-11 |
Anvar |
Nouveaux agents molluscicides derives du benzamido-2 nitro-5 thiazole
|
|
US4315018A
(en)
*
|
1978-12-07 |
1982-02-09 |
Rossignol Jean F |
Specific parasiticidal use of 2-benzamido-5-nitro-thiazole derivatives
|
|
AR226579A1
(es)
*
|
1979-12-21 |
1982-07-30 |
Wellcome Found |
Metodo para la preparacion de un compuesto de 2-benzoilimino-5-nitro-4-tiazolin-3-acetamida
|
|
US5387598A
(en)
*
|
1994-04-13 |
1995-02-07 |
Rossignol; Jean-Francois |
Composition and galenic formulation suitable for combatting affections of the lower abdomen
|
|
US5578621A
(en)
*
|
1994-09-08 |
1996-11-26 |
Romark Lab Lc |
Benzamide derivatives
|
|
PL186504B1
(pl)
*
|
1994-04-13 |
2004-01-30 |
Romark Lab |
Pochodne benzamidowe i kompozycje farmaceutyczne zawierające te pochodne
|
|
US5859038A
(en)
*
|
1994-09-08 |
1999-01-12 |
Romark Laboratories, L.C. |
Method for treatment of helicobacter pylori infections
|
|
US5968961A
(en)
*
|
1997-05-07 |
1999-10-19 |
Romark Laboratories, L.C. |
Pharmaceutical compositions of tizoxanide and nitazoxanide
|
|
MX9604483A
(es)
*
|
1994-09-08 |
1998-02-28 |
Jean-Francois Rossignol |
Derivados de benzamida, composiciones que contienen dicho derivado y uso de las mismas.
|
|
CN100515420C
(zh)
*
|
1997-05-07 |
2009-07-22 |
罗马克实验室有限公司 |
脱乙酰基硝噻醋柳胺和硝噻醋柳胺的药用组合物
|
|
AU756451B2
(en)
*
|
1997-05-07 |
2003-01-16 |
Romark Laboratories, L.C. |
Pharmaceutical compositions of tizoxanide and nitazoxanide
|
|
US5935591A
(en)
*
|
1998-01-15 |
1999-08-10 |
Romark Laboratories, L.C. |
Method for treatment of equine protozoal myeloencephalitis with thiazolides
|
|
US5925622A
(en)
*
|
1998-07-13 |
1999-07-20 |
Romark Laboratories, L.C. |
Synthesis of aryl glucuronide of 2-hydroxy-N- (5-nitro-2-thiazolyl) benzamide, and pharmaceutical compositions comprising same
|
|
SE0102764D0
(sv)
|
2001-08-17 |
2001-08-17 |
Astrazeneca Ab |
Compounds
|
|
US7125568B2
(en)
|
2001-08-23 |
2006-10-24 |
Sung Michael T |
Lipophilic drug compositions
|
|
GB0226930D0
(en)
|
2002-11-19 |
2002-12-24 |
Astrazeneca Ab |
Chemical compounds
|
|
GB0325402D0
(en)
*
|
2003-10-31 |
2003-12-03 |
Astrazeneca Ab |
Compounds
|
|
GB0327761D0
(en)
*
|
2003-11-29 |
2003-12-31 |
Astrazeneca Ab |
Compounds
|
|
GB0328178D0
(en)
*
|
2003-12-05 |
2004-01-07 |
Astrazeneca Ab |
Compounds
|
|
BRPI0507746A
(pt)
*
|
2004-02-18 |
2007-07-10 |
Astrazeneca Ab |
composto ou um sal, pró-droga ou solvato do mesmo, composição farmacêutica, método de tratar doenças mediadas por glk, e, processo para a preparação de um composto
|
|
KR20070007104A
(ko)
*
|
2004-02-18 |
2007-01-12 |
아스트라제네카 아베 |
화합물
|
|
TW200600086A
(en)
*
|
2004-06-05 |
2006-01-01 |
Astrazeneca Ab |
Chemical compound
|
|
UA90864C2
(en)
|
2004-09-09 |
2010-06-10 |
Ромарк Лебораториз, Л.К. |
Halogenated benzamide derivatives
|
|
US20060194853A1
(en)
*
|
2004-10-08 |
2006-08-31 |
Rossignol Jean F |
Alkyl benzamides
|
|
GB0423043D0
(en)
*
|
2004-10-16 |
2004-11-17 |
Astrazeneca Ab |
Compounds
|
|
KR20070085371A
(ko)
|
2004-10-16 |
2007-08-27 |
아스트라제네카 아베 |
페녹시 벤즈아미드 화합물의 제조 방법
|
|
GB0423044D0
(en)
*
|
2004-10-16 |
2004-11-17 |
Astrazeneca Ab |
Compounds
|
|
AU2006235490A1
(en)
*
|
2005-04-12 |
2006-10-19 |
Romark Laboratories, L.C. |
Methods for treating diseases through the function of molecular chaperones such as protein disulfide isomerases, pharmaceutical compositions comprising them, and screening methods for identifying therapeutic agents
|
|
EP1891069A1
(fr)
*
|
2005-05-24 |
2008-02-27 |
AstraZeneca AB |
Derives d'imidazol[4,5b]pyridine/pyrazine et purine substitues en 2-phenyl en tant que modulateurs de la glucokinase
|
|
TW200714597A
(en)
*
|
2005-05-27 |
2007-04-16 |
Astrazeneca Ab |
Chemical compounds
|
|
EP2027113A1
(fr)
*
|
2005-07-09 |
2009-02-25 |
AstraZeneca AB |
Dérivés d'hétéroaryl benzamide utilisés en tant qu'activateurs de la glk dans le traitement du diabète
|
|
JP2009500442A
(ja)
*
|
2005-07-09 |
2009-01-08 |
アストラゼネカ アクチボラグ |
2型糖尿病を処置するためのグルコキナーゼのモジュレーターとしての2−ヘテロシクリルオキシベンゾイルアミノヘテロシクリル化合物
|
|
KR101346902B1
(ko)
*
|
2005-07-09 |
2014-01-02 |
아스트라제네카 아베 |
당뇨병 치료에 있어 glk 활성화제로서 사용하기 위한헤테로아릴 벤즈아미드 유도체
|
|
US9202182B2
(en)
*
|
2005-08-11 |
2015-12-01 |
International Business Machines Corporation |
Method and system for analyzing business architecture
|
|
TW200738621A
(en)
*
|
2005-11-28 |
2007-10-16 |
Astrazeneca Ab |
Chemical process
|
|
CA2636527C
(fr)
|
2006-01-09 |
2016-05-17 |
Romark Laboratories, L.C. |
Traitement de l'hepatite virale
|
|
WO2008008480A2
(fr)
*
|
2006-07-12 |
2008-01-17 |
Cumbre Pharmaceuticals Inc. |
Dérivés de rifamycine contenant du nitrohétéroaryl
|
|
CN100465169C
(zh)
*
|
2006-08-02 |
2009-03-04 |
杭州欣阳三友精细化工有限公司 |
硝唑尼特的制备方法
|
|
TW200825063A
(en)
*
|
2006-10-23 |
2008-06-16 |
Astrazeneca Ab |
Chemical compounds
|
|
TW200825060A
(en)
*
|
2006-10-26 |
2008-06-16 |
Astrazeneca Ab |
Chemical compounds
|
|
KR20090090390A
(ko)
*
|
2006-12-21 |
2009-08-25 |
아스트라제네카 아베 |
Glk 활성제로서 유용한 신규 결정 화합물
|
|
CN101007792B
(zh)
*
|
2007-01-31 |
2010-05-26 |
浙江大学 |
一种合成硝基噻唑苯酰胺化合物的方法
|
|
ES2550755T3
(es)
|
2007-08-03 |
2015-11-12 |
Romark Laboratories, L.C. |
Compuestos de tiazolida sustituidos con alquilsulfonilo
|
|
EP2324028A2
(fr)
*
|
2008-08-04 |
2011-05-25 |
AstraZeneca AB |
Agents thérapeutiques 414
|
|
RS53347B
(sr)
|
2008-12-09 |
2014-10-31 |
Gilead Sciences, Inc. |
Modulatori toll-sličnih receptora
|
|
GB0902434D0
(en)
*
|
2009-02-13 |
2009-04-01 |
Astrazeneca Ab |
Chemical process
|
|
SI2395840T1
(sl)
|
2009-02-13 |
2020-08-31 |
Romark Laboratories, L.C. |
Farmacevtske formulacije nitazoksanida z nadzorovanim sproščanjem
|
|
GB0902406D0
(en)
*
|
2009-02-13 |
2009-04-01 |
Astrazeneca Ab |
Crystalline polymorphic form
|
|
AR076221A1
(es)
*
|
2009-04-09 |
2011-05-26 |
Astrazeneca Ab |
Derivado de pirazol [4,5-e] pirimidina y su uso para tratar diabetes y obesidad
|
|
WO2010116177A1
(fr)
|
2009-04-09 |
2010-10-14 |
Astrazeneca Ab |
Dérivé de pyrazolo [4,5-e] pyrimidine et son utilisation pour traiter le diabète et l'obésité
|
|
NZ596538A
(en)
|
2009-05-12 |
2014-04-30 |
Romark Lab Lc |
Haloalkyl heteroaryl benzamide compounds
|
|
CN108042535A
(zh)
|
2009-06-26 |
2018-05-18 |
罗马克实验室有限公司 |
用于治疗流感的化合物和方法
|
|
CN101602744B
(zh)
*
|
2009-06-30 |
2011-06-01 |
青岛康地恩药业有限公司 |
一种硝唑尼特的制备方法
|
|
WO2013110975A1
(fr)
|
2012-01-27 |
2013-08-01 |
Siegfried Rhein S.A. De C.V. |
Composition de nitazoxanide améliorée et son procédé de préparation
|
|
WO2014049397A1
(fr)
|
2012-09-27 |
2014-04-03 |
Siegfried Rhein S.A. De C.V. |
Composition synergique de nitazoxanide et de mébendazole, procédés de préparation correspondants et utilisation de cette composition dans le traitement de la parasitose humaine
|
|
EP3010345A4
(fr)
*
|
2013-06-21 |
2017-04-12 |
The Regents of The University of California |
Potentiel thérapeutique étendu dans des antimicrobiens à nitrohétéroaryle
|
|
JP6522732B2
(ja)
|
2014-07-11 |
2019-05-29 |
ギリアード サイエンシーズ, インコーポレイテッド |
Hivを治療するためのトール様受容体の調節因子
|
|
SG11201701520TA
(en)
|
2014-09-16 |
2017-04-27 |
Gilead Sciences Inc |
Solid forms of a toll-like receptor modulator
|
|
MX2017006083A
(es)
|
2014-11-11 |
2017-11-08 |
Romark Laboratories Lc |
Composicones y metodos de tratamiento con profarmacos de tizoxanida, un analogo o sal de la misma.
|
|
CN105175352A
(zh)
*
|
2015-10-27 |
2015-12-23 |
杭州澳医保灵药业有限公司 |
一种硝唑尼特的制备方法
|
|
CN106831640A
(zh)
*
|
2015-12-03 |
2017-06-13 |
江苏正大丰海制药有限公司 |
一种硝唑尼特晶体的制备方法
|
|
PT3436074T
(pt)
|
2016-03-31 |
2020-08-21 |
Romark Laboratories Lc |
Compostos tiazolida para tratamento de infeções virais
|
|
JP6894923B2
(ja)
|
2016-04-11 |
2021-06-30 |
ジェンフィGenfit |
胆汁うっ滞性及び線維性の疾患の処置方法
|
|
US11033534B2
(en)
|
2017-01-27 |
2021-06-15 |
Genfit |
Pharmaceutical compositions for combination therapy
|
|
WO2018195035A1
(fr)
|
2017-04-18 |
2018-10-25 |
Romark Laboratories L.C. |
Inhibition de la protéine disulfure-isomérase a3
|
|
WO2019241376A1
(fr)
|
2018-06-14 |
2019-12-19 |
The Trustees Of Columbia University In The City Of New York |
Traitement de troubles cognitifs à l'aide de nitazoxanide (ntz), d'analogues de nitazoxanide (ntz) et de leurs métabolites
|
|
CA3130518A1
(fr)
|
2019-04-12 |
2020-10-15 |
Nicolas STANKOVIC-VALENTIN |
Nitazoxanide et thiazolides destines a etre utilises dans le traitement de maladies associees au stress oxydatif
|
|
TWI810456B
(zh)
|
2019-05-22 |
2023-08-01 |
美商基利科學股份有限公司 |
Tlr7調節化合物及hiv疫苗之組合
|
|
JP7741800B2
(ja)
|
2019-10-28 |
2025-09-18 |
ジェンフィット |
抗酸化性質を有する併用療法
|
|
US20230303504A1
(en)
|
2020-07-20 |
2023-09-28 |
Romark Laboratories, L.C. |
Crystalline salts of tizoxanide and 2-hydroxy-n-(5-chloro-1,3-thiazol-2-yl)benzamide (rm-4848) with ethanolamine, morpholine, propanolamine, piperazine and n-methylpiperazine
|
|
MX2023002208A
(es)
|
2020-08-24 |
2023-05-17 |
Romark Laboratories Lc |
Uso de tiazolidas contra los coronavirus.
|
|
CN114044761B
(zh)
*
|
2021-02-24 |
2022-05-17 |
成都贝诺科成生物科技有限公司 |
一种新的硝基噻唑衍生物及其应用
|
|
CN115197164B
(zh)
*
|
2021-04-12 |
2025-04-01 |
杜心赟 |
新型噻唑类化合物及其制备方法和用途
|
|
WO2023058046A1
(fr)
|
2021-10-05 |
2023-04-13 |
Council Of Scientific And Industrial Research An Indian Registered Body Incorporated Under The Regn. Of Soc. Act (Act Xxi Of 1860) |
Procédé amélioré pour préparer du nitazoxanide et de ses intermédiaires
|
|
WO2023198095A1
(fr)
*
|
2022-04-12 |
2023-10-19 |
成都贝诺科成生物科技有限公司 |
Utilisation d'un dérivé de nitrothiazole dans la préparation d'un bactériostatique pour inhiber helicobacter pylori
|